{"id":"NCT01801735","sponsor":"Iroko Pharmaceuticals, LLC","briefTitle":"Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip","officialTitle":"A Multicenter, Open-Label, Safety Study of Meloxicam SoluMatrixâ„¢ Capsules in Subjects With Osteoarthritis of the Knee or Hip","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-06","completion":"2014-08","firstPosted":"2013-03-01","resultsPosted":"2015-05-12","lastUpdate":"2015-05-12"},"enrollment":600,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis"],"interventions":[{"type":"DRUG","name":"Meloxicam Test Capsules","otherNames":[]}],"arms":[{"label":"Meloxicam Test Capsules","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety of Meloxicam SoluMatrix Capsules for up to 52 weeks in subjects with pain due to osteoarthritis (OA) of the knee or hip","primaryOutcome":{"measure":"Safety of Meloxicam 10 mg as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination","timeFrame":"Baseline to Week 52/Early Termination","effectByArm":[{"arm":"Meloxicam 10 mg","deltaMin":406,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":600},"commonTop":["Arthralgia","Urinary tract infection"]}}